Disruption of p53 in human cancer cells alters the responses to therapeutic agents

Journal of Clinical Investigation

Volumn 104, Issue 3, 1999, Pages 263-269

  Bunz, Fred ^a   Hwang, Paul M ^b,c   Torrance, Chris ^a,b   Waldman, Todd ^d   Zhang, Yonggang ^a   Dillehay, Larry ^a   Williams, Jerry ^a   Lengauer, Christoph ^a   Kinzler, Kenneth W ^a   Vogelstein, Bert ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; FLUOROURACIL; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; COLON CANCER; COLORECTAL CANCER; DNA DAMAGE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032701521     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI6863     Document Type: Article

References (33)

1. Ko, L.J., and Prives, C. 1996. p53: puzzle and paradigm. Genes Dev. 10:1054-1072.
2. Levine, A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell. 88:323-331.
3. Blandino, G., Levine, A.J., and Oren, M. 1999. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene. 18:477-485.
4. Morrow, C.S., and Cowan, K.H. 1998. Drug resistance and its clinical circumvention. In Cancer medicine. Volume 1, 4th edition. J.R. Holland et al., editors. Lea and Febiger. Philadelphia, PA. 799-815
5. Benhattar, J., Cerottini, J.P., Saraga, E., Metrhez, G., and Givel, J.C. 1996. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int. J. Cancer. 6:190-192.
6. Brett, M.C., et al. 1996. p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur. J. Surg. Oncol. 12:182-185.
7. Luna-Perez, P., Arriola, E.L., Cuadra, Y., Alvarado, I., and Quintero, A. 1998. p53 protein overexpression and response to induction chemoradiation therapy in patients with locally advanced rectal adenocarcinoma. Ann. Surg. Oncol. 5:203-208.
8. Hall, P.A., and Lane, D.P. 1994. p53 in tumour pathology: can we trust immunohistochemistry? - Revisited! J. Pathol. 172:1-4.
9. Lowe, S.W., et al. 1994. p53 status and the efficacy of cancer therapy in vivo. Science. 266:807-810.
10. Hawkins, D.S., Demers, G.W., and Galloway, D.A. 1996. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 56:892-898.
11. O'Connor, P.M., et al. 1997. Characterization of the p53 tumor suppressor path way in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57.4285-4300.
12. Klingelhutz, A.J., Foster, S.A., and McDougall, J.K. 1996. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature. 380:79-82.
13. Sedivy, J.M., et al. 1999. Gene targeting in human cells without isogenic DNA. Science. 283:9.
14. Bunz, F., et al. 1998. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 282:1497-1501.
15. Waldman, T., Kinzler, K.W., and Vogelstein, B. 1995. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55:5187-5190.
16. Waldman, T., et al. 1997. Cell cycle arrest versus cell death in cancer therapy. 1997. Nat. Med. 3:1034-1036.
17. Brugarolas, J., et al. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature. 377:552-557.
18. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 82:675-684.
19. Waldman, T., Lengauer, C., Kinzler, K.W., and Vogelstein, B. 1996. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature. 381:713-716.
20. Parker, W.B., and Cheng, Y.C. 1990. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol. Ther. 48:381-395.
21. Geoffroy, F.J., Allegra, C.J., Sinha, B., and Grem, J.L. 1994. Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells. Oncol. Res. 6:581-591.
22. Wyllie, A.H. 1997. Apoptosis and carcinogenesis. Eur. J. Cell Biol. 73:189-197.
23. Fisher, D.E. 1994. Apoptosis in cancer therapy: crossing the threshold. Cell. 78:539-542.
24. Lowe, S.W. 1995. Cancer therapy and p53. Curr. Opin. Oncol. 7:547-553.
25. Weller, M. 1998. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res. 292:435-445.
26. Pritchard, D.M., Watson, A.J., Potten, C.S., Jackman, A.L., and Hickman, J.A. 1997. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc. Natl. Acad. Sci. USA. 94:1795-1799.
27. Cory, J.G., Breland, J.C., and Carter, G.L. 1979. Effect of 5-fluorouracil on RNA metabolism in Novikoff hepatoma cells. Cancer Res. 39:4905-4913.
28. Hermeking, H., et al. 1997. 14-3-3σ is a p53-regulated inhibitor of G2/M progression. Mol. Cell 1:3-8.
29. Vayssiere, J.L., Petit, P.X., Risler, Y., and Mignotte, B. 1994. Commitment to apoptosis is associated with changes in mitochondrial biogenesis and activity in cell lines conditionally immortalized with simian virus 40. Proc. Natl. Acad. Sci. USA. 91:11752-11756.
30. Johnson, T.M., Yu, Z.-X., Ferrans, V.J., Lowenstein, R.A., and Finkel, T. 1996. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc. Natl. Acad. Sci. USA. 93:11848-11852.
31. Polyak, K., Xia, Y., Zweier, J.L., Kinzler, K.W., and Vogelstein, B. 1997. A model for p53-induced apoptosis. Nature. 389:300-305.
32. Green, D.R., and Reed, J.C. 1998. Mitochondria and apoptosis. Science. 281:1309-1312.
33. Lamb, J.R., and Friend, S.H. 1997. Which guesstimate is the best guesstimate? Predicting chemotherapeutic outcomes. Nat. Med. 3:962-963.